If you're a qualified researcher studying growth-hormone-releasing pathways, you've almost certainly encountered two distinct variants of the CJC-1295 peptide: the standard form and the DAC (Drug Affinity Complex) form. Choosing between them shapes your entire experimental design. At PeptideValidation.com, research-grade CJC-1295 is supplied as a 5 mg lyophilized powder for exactly these kinds of controlled laboratory studies, and understanding the structural differences between variants is the first step toward reproducible results.

What Is the CJC-1295 Peptide? A Definitional Overview

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of 30 amino acids. It is designed to stimulate pituitary GHRH receptors in laboratory models, prolonging growth-hormone-related signalling. Two research variants exist: CJC-1295 without DAC (short-acting) and CJC-1295 with DAC (long-acting), differing primarily in plasma half-life and binding mechanism.

CJC-1295 was originally developed to address a core limitation of natural GHRH: its rapid enzymatic degradation in plasma, with a biological half-life of under 10 minutes. Researchers modified the peptide backbone at specific positions to resist cleavage by dipeptidyl peptidase IV (DPP-IV), extending its useful research window considerably.

The variant without DAC (sometimes labelled Modified GRF 1-29 in research literature) retains a half-life of roughly 30 minutes in vitro. The DAC variant adds a lysine-maleimidopropionic acid linker that forms a covalent bond with serum albumin. That bond extends the half-life to approximately 7 to 10 days in animal studies, a dramatic difference with direct implications for experimental scheduling.

Neither form is approved for human or veterinary use. Both are research compounds intended for qualified laboratories conducting endocrine, metabolic, or peptide-signalling studies. Researchers sourcing either variant should confirm purity levels above 98% via HPLC and verify molecular weight through mass spectrometry before beginning any experiment.

For newcomers to this area, a useful starting point is the full structural and mechanistic background available in our CJC-1295 peptide complete research guide, which covers receptor pharmacology in greater depth.

Structural Differences Between the Two Variants

The core structural difference is a maleimidopropionic acid (MPA) group attached via a lysine residue in the DAC form. This group reacts with cysteine-34 on serum albumin, creating a long-circulating depot. The non-DAC form lacks this linker entirely, clearing from the system within minutes to hours.

At the amino acid sequence level, both variants share the same 30-residue GHRH backbone with substitutions at positions 2, 8, 15, and 27 that confer DPP-IV resistance. The key divergence is the C-terminal modification.

In the non-DAC form, the C-terminus ends with an amide group, which improves receptor affinity but provides no albumin-binding capacity. In the DAC variant, the same terminus carries the MPA linker. Think of it as attaching a molecular anchor that keeps the peptide tethered to circulating albumin rather than clearing through renal filtration.

For laboratory applications, this matters in several concrete ways. Researchers studying pulsatile versus sustained signalling patterns need different variants for each paradigm. Pulsatile GHRH-receptor studies, which aim to mimic physiological secretory bursts, are better modeled with the short-acting form. Sustained receptor occupancy experiments benefit from the DAC form's prolonged presence.

Mass spectrometry confirms these structural differences precisely. The non-DAC form has a molecular weight of approximately 3,368 Da, while the DAC form registers closer to 3,647 Da. Any COA from a qualified vendor should report these values to the nearest decimal, and a discrepancy of more than 2 Da warrants rejection of the batch.

Half-Life and Experimental Timeline Implications

CJC-1295 without DAC has an estimated half-life of 30 minutes in plasma. CJC-1295 with DAC extends this to approximately 7 to 10 days due to albumin binding. Researchers must align dosing intervals and sample collection windows to whichever half-life their model requires.

Half-life is not just a pharmacokinetic footnote. It determines when you collect samples, how often you introduce the compound into your model system, and how you interpret downstream data.

With the non-DAC form, a single administration in an animal model produces a measurable GH pulse within 15 to 30 minutes, with levels returning to near-baseline within 2 to 3 hours. This tight window is actually an asset for researchers who want to map discrete signalling events. It gives you a clean before-and-after snapshot.

The DAC variant behaves more like a slow-release depot. After a single administration, circulating levels remain elevated for days, which means cumulative effects compound across the study period. This suits long-duration metabolic studies but complicates any design that requires a washout phase. Researchers in endocrine labs have noted that inter-animal variability also increases with the DAC form because small differences in albumin concentration between subjects affect clearance rates differently.

Practically speaking, study designs using the non-DAC form typically require more frequent compound introductions, which increases both material consumption and researcher time. A 14-day study using the non-DAC form at daily intervals consumes roughly 14 times the compound compared to a single-administration DAC study over the same period. Budget your 5 mg lyophilized vial accordingly when planning your protocol.

Sample collection timing is equally critical. For the non-DAC form, plasma sampling at 15, 30, 60, and 120 minutes post-administration captures the full response curve. For the DAC form, daily sampling over 7 to 10 days is more appropriate.

CJC-1295 Dosage Context for Laboratory Research

Published preclinical research on CJC-1295 peptide dosage in animal models typically reports ranges of 30 to 300 micrograms per kilogram for the non-DAC form, administered subcutaneously. CJC-1295 with DAC dosage in rodent studies commonly falls in the 20 to 60 microgram per kilogram range, given once every 5 to 7 days to align with its extended half-life.

Dosage context in research is highly model-specific. The figures cited in peer-reviewed literature are not transferable to other species or experimental conditions without careful allometric scaling. They are reference points, not universal protocols.

For CJC-1295 with DAC dosage, the longer half-life means cumulative exposure builds across administrations. Researchers running multi-week studies should account for this accumulation when interpreting IGF-1 or GH surrogate marker data at later time points. Several published studies use once-weekly administration in rodent models at approximately 40 micrograms per kilogram, chosen because it approximates steady-state conditions after the third dose.

With the non-DAC form, daily subcutaneous administration in rodent models is more common, with doses ranging from 50 to 150 micrograms per kilogram depending on the endpoint being studied. Because the compound clears rapidly, there is less concern about accumulation, but consistent timing relative to the light cycle matters in models where GH secretion is circadian-sensitive.

Always work from your institution's approved protocol. Dose selection should be informed by published literature, pilot data from your own lab, and the specific biological endpoints you are measuring. PeptideValidation.com's 5 mg lyophilized format gives researchers enough material for a full dosing matrix in standard rodent studies without requiring mid-study reorder delays that could introduce batch variability.

Reported Observations and CJC-1295 Side Effects in Preclinical Data

Preclinical studies examining CJC-1295 peptide side effects in animal models have noted transient injection-site reactions, mild hypoglycemia at high doses, and changes in cortisol or prolactin in some rodent studies. These observations are model- and dose-dependent and do not predict human outcomes.

Understanding observed effects in preclinical data is part of rigorous experimental design. Researchers need to know what to monitor so they can distinguish compound-related signals from experimental noise.

The most consistently reported observation across rodent studies is a transient suppression of blood glucose in the 60 to 90 minutes following administration, particularly at the higher end of published dose ranges. This is consistent with the downstream effects of elevated GH on insulin sensitivity in animal models. Laboratories running metabolic endpoints should include glucose monitoring in their standard panel.

Injection-site reactions, including localized erythema and minor swelling, have been reported in some subcutaneous administration models. These are generally transient and resolve within 24 hours. Their frequency appears higher in repeated-administration protocols, which is relevant for studies using the non-DAC form at daily intervals.

A question researchers sometimes raise is: is CJC-1295 a steroid? The answer is definitively no. CJC-1295 is a peptide, meaning it is composed of amino acid residues joined by peptide bonds. It has no steroidal ring structure and no mechanism of action comparable to anabolic or corticosteroid compounds. This distinction matters for experimental design and for regulatory classification of the compound in your laboratory's inventory.

CJC-1295 peptide benefits observed in preclinical literature include measurable increases in GH pulse amplitude, elevated IGF-1 in plasma, and changes in lean tissue composition in some long-duration rodent studies. These are research observations, not therapeutic claims.

Quality Verification: What to Check Before You Order

Before sourcing any CJC-1295 peptide, researchers should verify: (1) HPLC purity above 98%, (2) mass spectrometry confirmation of correct molecular weight, (3) batch-specific COA with lot number, (4) documented storage conditions (typically -20 degrees C lyophilized), (5) third-party independent lab testing, and (6) vendor transparency on manufacturing origin.

Quality verification is not optional. A peptide that fails purity or identity testing invalidates every data point built on it, and you won't know the data is flawed until you try to replicate the study.

Start with the COA. A credible COA for CJC-1295 will report HPLC purity as a percentage (98% or above is the standard research-grade threshold), a mass spectrometry readout confirming the molecular ion, a batch or lot number, a manufacturing date, and recommended storage conditions. Any vendor that cannot provide a batch-specific COA should be disqualified immediately.

Third-party testing is the next filter. Internal COAs generated by the manufacturer carry an inherent conflict of interest. Independent laboratory verification, from a facility with no commercial relationship to the vendor, provides the confirmation that researchers can cite in publications and institutional compliance reports.

PeptideValidation.com's vendor certification process applies these criteria systematically. Certified vendors are evaluated on sourcing transparency, COA availability, independent testing documentation, quality management systems, and technical support responsiveness. For researchers who want to understand the full framework, the PeptideValidation.com CJC-1295 research guide covers COA review methodology in detail.

Storage matters too. Lyophilized CJC-1295 powder should be stored at -20 degrees C and protected from light. Once reconstituted in bacteriostatic water, use within 4 weeks if refrigerated. Record the reconstitution date on every vial. Sloppy storage documentation is one of the most common sources of unexplained inter-experiment variability in peptide research.

Which Form Fits Your Research Model? A Practical Decision Guide

Choose CJC-1295 without DAC for pulsatile, short-window signalling studies and designs that require frequent dosing control. Choose CJC-1295 with DAC for sustained receptor occupancy studies, long-duration metabolic experiments, or protocols where infrequent administration is operationally necessary.

The decision between the two CJC-1295 peptide variants comes down to three questions: What signalling pattern are you modeling? How long is your study? And how much operational flexibility does your team have?

If your hypothesis centers on pulsatile GH secretion, discrete receptor activation events, or short-window pharmacodynamic mapping, the non-DAC form is the appropriate tool. Its rapid clearance gives you a clean experimental signal that is easy to attribute to a single administration event.

If your study runs longer than 2 weeks, examines cumulative metabolic endpoints like body composition or bone density surrogate markers, or requires minimal handling stress on your animal subjects, the DAC form reduces the number of administrations substantially. Fewer injections also means less handling-induced cortisol elevation, which can confound GH-axis data in rodent models.

Budget is a practical factor too. Researchers on tight material budgets often find the DAC form more economical per study week because the reduced administration frequency stretches a 5 mg vial further across a multi-week protocol. For a 21-day rodent study with 10 subjects, a daily non-DAC protocol at 100 micrograms per kilogram in 25-gram mice consumes approximately 0.75 mg of compound per animal over the study period. A once-weekly DAC protocol at 40 micrograms per kilogram in the same model consumes roughly 0.12 mg per animal. The arithmetic is straightforward.

When in doubt, pilot both variants in a small cohort before committing to a full study. Pilot data saves far more time and material than a failed full-scale experiment.

Frequently asked questions